China Biologic Products (CBPO) Tops Q2 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Jefferies Raises Price Target on China Biologic Products (CBPO) to $155; Reiterates Buy
August 8, 2016 8:07 AM EDTJefferies reiterated a Buy rating on China Biologic Products (NASDAQ: CBPO), and raised the price target to $155.00 (from $136.00), following the company's 2Q earnings report. Total sales revenue was up 15.6% yoy and Non-GAAP net income was up 23.0% yoy despite fx drag.
Analyst Kevin Zhao... More
